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Abstract
Background: Data on hospital-acquired venous thromboembolism (HA-VTE) incidence, case fatality rate and variation
amongst patient groups and health providers is lacking. We aim to explore HA-VTE incidences, associated mortality,
trends and variations across all acute hospitals in New South Wales (NSW)-Australia.
Methods: A population-based study using all admitted patients (aged 18–90 with a length of stay of at least two days
and not transferred to another acute care facility) in 104 NSW acute public and private hospitals during 2002–2009.
Poisson mixed models were used to derive adjusted rate ratios (IRR) in presence of patient and hospital characteristics.
Results: Amongst, 3,331,677 patients, the incidence of HA-VTE was 11.45 per 1000 patients and one in ten who
developed HA-VTE died in hospital. HA-VTE incidence, initially rose, but subsequently declined, whereas case fatality
rate consistently declined by 22 % over the study period. Surgical patients were 128 % (IRR = 2.28, 95 % CI: 2.19–2.38)
more likely to develop HA-VTE, but had similar case fatality rates compared to medical patients. Private hospitals, in
comparison to public hospitals had a higher incidence of HA-VTE (IRR = 1.76; 95 % CI: 1.42–2.18) for medical patients.
However, they had a similar incidence (IRR = 0.91; 95 % CI: 0.75–1.11), but a lower mortality (IRR = 0.59; 95 % CI: 0.47–0.75)
amongst surgical patients. Smaller public hospitals had a lower HA-VTE incidence rate compared to larger
hospitals (IRR < 0.68) but a higher case fatality rate (IRR > 1.71). Hospitals with a lower reported HA-VTE incidence tended
to have a higher HA-VTE case fatality rate.
Conclusion: Despite the decline in HA-VTE incidence and case fatality, there were large variations in incidents between
medical and surgical patients, public and private hospitals, and different hospital groups. The causes of such differences
warrant further investigation and may provide potential for targeted interventions and quality improvement initiatives.
Keywords: Hospital acquired complication, Patient safety, Quality improvement, Venous thromboembolism
Background
Venous thromboembolism (VTE), comprising both deep
venous thrombosis (DVT) and pulmonary embolism
(PE) are potentially preventable and treatable medical
conditions that can contribute to patient morbidity and
mortality [1, 2]. VTE accounts for almost 10 % of all
hospital deaths [3], and over half of VTE incidents are
hospital acquire (HA-VTE) [4–6]. Appropriate interven-
tion (e.g. pharmacological and mechanical prophylaxis),
can significantly reduce the incidence of VTE by 70 % for
both medical and surgical patients [7–9]. Evidence-based
VTE prevention and treatment guidelines [1, 10, 11] have
been developed so as to reduce VTE occurrence and have
been adopted for both accreditation and benchmarking
[12, 13].
In the U.S the incidence, and fatality rates, of HA-VTE
following surgery have decreased by 50 and 30 %
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respectively [14–16]. Effective implementation of VTE
prevention and treatment protocols may have contribu-
ted to the decreased rates in the U.S. hospitals [17]. Sub-
stantial variation in trends and rates amongst similar
hospitals [14], after adjustment for case mix and surgery
types [18, 19], may reflect variation in compliance with
VTE prevention strategies and the potential for further
improvement [20]. In contrast, there has been a 30 % in-
crease in post-operative VTE incidents in Australian
hospitals [21].
There have been few studies of the HA-VTE incidence
and subsequnt mortality in Australia [21–24]. In this
study, we adopted a validated measure of HA-VTE to
explore trends in the rates of HA-VTE, and associated
mortality amongst admitted patients to all acute public
and private hospitals in New South Wales (NSW),
Australia between 2002 and 2009. Patients’ and hospitals’
contributing factors to the HA-VTE trends and varia-
tions were also examined.
Methods
Data source and study population
We used records from the NSW Admitted Patient Data
Collection (APDC) database. It includes all admitted pa-
tients in NSW public and private, acute, sub-acute and
non-acute facilities, and is used for health services planning,
funding and research. Reporting to APDC is mandatory at
all hospitals. The APDC includes information on patient
demographics, medical conditions and procedures, hospital
characteristics, and separations (discharges, transfers and
deaths) from all public and private healthcare facilities in
NSW. Each episode of care in the APDC is assigned with
up to 55 codes for morbidities (principal diagnosis and co-
morbidities) based on the International Statistical Classifi-
cation of Diseases and Related Health Problems, Tenth
Revision, Australian Modification (ICD-10-AM) 4th edition
[25]. The codes are assigned by trained and qualified
clinical coders based on clinical notes and according to
standards [26]. The quality of data was found reason-
able, but varied across data elements and hospitals [27–29].
In NSW public hospitals accommodated 62 % of all
patients’ admissions, with a greater proportion of over-
night stays (70 %), but a similar same-day stays (51 %)
compared to private hospitals. Over 80 % of funding for
public and private hospitals were provided by govern-
ment and health insurers respectively [30]. All admis-
sions, between 1st January 2002 to 31st December 2009,
from 104 of 497 NSW acute public and private hospitals
(11,408,808, admissions; 71 %) were included. We ex-
cluded community, non-acute, psychiatric and rehabili-
tation facilities, nursing home and hospices, and the two
children’s hospitals.
Included were patients who had a hospital length of
stay (LOS) of at least two days, aged between 18 and
90 years (inclusive), and were not transferred to another
acute care facility (4,089,144 episodes (35.8 %)).
HA-VTE identification and covariates
Based on ICD-10-AM, we considered the codes I26 (.0)
and I26.9 for PE and I80.1, I80.2, I80.3, I80.8, I80.9,
I82.8, and I82.9 for DVT cases - a total of nine VTE
diagnosis codes. VTE codes were chosen according to
well-established VTE related measures within a quality
and safety context [12, 31, 32] and existing published
coding procedures [19, 22]. Cases with no VTE code as
the principal diagnosis were identified as patients at risk
and those who had at least one VTE code in secondary
diagnoses were identified as HA-VTE cases. It resulted
in exclusion of patients with VTE as principal diagnoses
from both numerator and denominator. Obstetric pa-
tients, identified by major diagnosis category using Aus-
tralian Refined Diagnosis Related Groups (AR-DRG)
[25], and those surgical patients who only had a pro-
cedure for interruption of vena cava (ICD codes: 348000,
3533000 and 3533001) were excluded from the study
population as suggested within a patient safety context in
Australia [32] and elsewhere [31, 33]. The discharge status
(alive or deceased) was used to derive the case fatality asso-
ciated with a HA-VTE diagnosis. HA-VTE cases and re-
lated deaths were respectively presented as incidence rate
(per 1000 admissions) and case fatility.
For all admissions, two sets of patient- and hospital-
related covariates were considered. Patient demographic
variables included age, gender, country of birth, marital
status, patient socio-economic status, principal diagnostic
disease groups (the ten most common groups based on
Elixhauser comorbidities [34]), and length of stay within
the study population. We utilised a postcode-level advan-
tage and disadvantage index of Socio-Economic Indices
for Areas (SEIFA) with the lower values indicating more
disadvantaged areas [35]. SEIFA scores were categorised
into four classes (1st quartile =most disadvantaged areas
and 4th quartile =most advantaged areas). The disease
groups were identified using principal diagnostic codes
(ICD-10-AM) at admissions through the methodology de-
veloped by Quan et al. [34]. Admissions with any surgical
codes recored as the principal procedure were categorised
as surgical admissions and those with no procedural data
were categorised as medical admissions. Using relevant
procedure codes from ICD-10-AM (Additional file 1), we
defined six major surgical procedures including coronary-
artery bypass graft (CABG), abdominal aortic aneurysm
(AAA) repair, total hip replacement, total knee replace-
ment, cholecystectomy, and other surgical procedures.
Hospital covariates included the local health district
(metropolitan, rural and regional NSW), the hospital
type (public and private), and associated peer groups.
Public hospital peer groups included “A1”: principal
Assareh et al. BMC Health Services Research  (2016) 16:511 Page 2 of 10
referral group, usually teaching hospitals; “A3”: ungrouped
acute; “B”: major metropolitan and non-metropolitan;
“C1”: district group 1; and, “C2”: district group 2. Private
hospital peer groups included “21”: major; and “22”: dis-
trict group hospitals. Hospital peer groups contained simi-
lar type and sized hospitals, ranging from those treating
more than 25,000 acute case-mix weighted separations
per annum in principal referral groups through to treating
2000+ (but less than 5000) acute case-mix weighted sepa-
rations per annum in district group [36].
Statistical analysis
We employed Poisson mixed models to evaluate ad-
justed incidence and case fatality rates and rate ratios for
both study outcomes after including all patients and
hospital-related characteristics. A random intercept term
was utilised to incorporate any clustering effect at
hospital-level. Stratified models were constructed to de-
rive estimates for specific admission types (medical and
surgical) and hospital peer groups (public and private)
separately. To investigate the temporal pattern of the
outcomes, calendar years were entered into the model as
indicator variables, with 2002 as the reference year. A
model with the year as a continuous variable was also
examined for linear trends. We derived specific trends
for hospital types, admission type, peer group and surgery
type using separate models. Adjusted rates for specific
years were derived by multiplying yearly-adjusted rate ra-
tios to the crude rates observed in the reference year.
We did not include either the Elixhauser or the Charlson
Index comorbidities in the models due to an approximately
unexpected 50 % drop (see Additional file 2) observed in
the indices among our study population in recent years
[21], and also reported geographical variations and biases
in the coding that may lead to misleading results [37, 38].
For example, it was reported that there is an increased
under-recording of diabetes conditions in APDC datasets
between 2008 and 2012 [39].
To study the variation of outcomes across hospitals
within each hospital group, hospital-specific random inter-
cept components were extracted from stratified Poisson
mixed models constructed for each hospital group, then
ranked and categorised into five classes at 20 % incre-
mental quintiles. To obtain adjusted differences be-
tween those with the highest and those with the lowest
HA-VTE and HA-VTE case fatality rates, the adjusted
classes were entered into a Poisson model including pa-
tient characteristics covariates. We then used Pearson
correlation to assess the association of hospital perfor-
mances between HA-VTE and post HA-VTE deaths,
based on the hospital-specific random intercepts. All
analyses were performed in R package version 3.0.0
[40] and Stata™ 11.0 [41].
Result
The distributions of study outcomes by patient and
hospital characteristics
Of the 3,331,677 admissions during 2002–2009 with a me-
dian LOS of five days (1st and 3rd quartiles: 3, 9 days), 38,161
patients developed a HA-VTE, resulting in an incidence rate
of 11.4 per 1000 patients (median LOS = 12, quartiles: 7–22
days; Table 1). Among them, 3716 (9.7 %) died in hospitals
(median LOS= 13, quartiles: 7–25 days). Patients who
underwent surgery (elective or non-elective, 83 % of all in-
cluded patients) accounted for 93.3 % of HA-VTE cases and
were 2.3 times more likely to develop HA-VTE compared
to medical patients, but had a similar mortality rate. Com-
pared to females, male patients were less likely to develop a
HA-VTE (IRR = 0.93) but more likely to die (IRR = 1.25).
HA-VTE incidence and associated case fatality were higher
among elderly. Patients who stayed longer in hospitals
had higher HA-VTE incidences but lower fatalities.
Patients who were born in Europe (except the UK),
Asia and North Africa experienced a lower risk of post-
operative HA-VTE but a similar risk of death. Higher
socio-economic status (quartiles of SEIFA) was associ-
ated with a higher risk of post HA-VTE death, in particu-
lar for surgical patients. Surgical and medical patients
admitted with pulmonary circulation or coagulopathy dis-
orders had the highest HA-VTE incidences, followed by
cancer patients who had the highest fatality rate. Patients
who underwent total knee replacement, AAA repair and
total hip replacement surgeries had a higher risk of
HA-VTE. However, post HA-VTE mortality was lower
amongst orthopaedic surgical patients, compared to
other surgical patients (see Additional file 3).
For medical patients, HA-VTE incidence was signifi-
cantly higher in private hospitals compared to public hos-
pitals (IRR = 1.76), whereas for surgical patients it was
similar (see Additional files 3 and 4). The risk of death in
private hospitals was almost half of the risk in public hos-
pitals, in particular for surgical patients.
Among public hospitals, patients from principal referral
hospitals were more likely to acquire VTE during hospital-
isation in comparison to patients from smaller hospitals.
However, patients admitted to smaller hospitals, were at a
higher risk of death. This pattern was almost consistent
across medical and surgical patients (see Additional
files 3 and 4). No differences in outcomes were observed
between private hospital peer groups.
The trends of HA-VTE incidence rate and HA-VTE case
fatality over the study period
HA-VTE incidence rate increased by 14 % between 2002
and 2004 reaching an adjusted incidence rate of 12.4 per
1000 patients, and then declined during the rest of the study
period (Fig. 1). The increase in the HA-VTE incidence rate
between 2002 and 2004 occurred in surgical but not
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Table 1 Study population, incidence rates and adjusted rate ratios of patients who developed HA-VTE and associated case fatality
Characteristics All Patients HA-VTE HA-VTE case fatality
N (%) n (%) IR IRR (95 % CI) n (%) % IRR (95 % CI)
Admission typea
Medical 573,042 (17.20 %) 2,565 (6.72 %) 4.5 1.00 245 (6.59 %) 9.6 % 1.00
Surgical 2,758,635 (82.80 %) 35,596 (93.28 %) 12.9 2.28 (2.19–2.38) d 3,471 (93.41 %) 9.8 % 1.05 (0.91–1.20)
Sex
Female 1,693,109 (50.82 %) 19,805 (51.90 %) 11.7 1.00 1,730 (46.56 %) 8.7 % 1.00
Male 1,638,568 (49.18 %) 18,356 (48.10 %) 11.2 0.93 (0.91–0.95) d 1,986 (53.44 %) 10.8 % 1.25 (1.17–1.33) d
Age
> =75 years & <90 1,074,206 (32.24 %) 15,350 (40.22 %) 14.3 1.00 1,832 (49.30 %) 11.9 % 1.00
> =18 years & <35 years 396,444 (11.90 %) 1,742 (4.56 %) 4.4 0.53 (0.50–0.56) d 55 (1.48 %) 3.2 % 0.23 (0.17–0.30) d
> =35 years & <55 years 707,274 (21.23 %) 5,612 (14.71 %) 7.9 0.83 (0.81–0.86) d 354 (9.53 %) 6.3 % 0.47 (0.41–0.52) d
> =55 years & <75 years 1,153,753 (34.63 %) 15,457 (40.50 %) 13.4 1.13 (1.10–1.15) d 1,475 (39.69 %) 9.5 % 0.77 (0.72–0.83) d
Marital status
Married 1,803,208 (54.12 %) 20,814 (54.54 %) 11.5 1.00 2,089 (56.22 %) 10.0 % 1.00
Single 1,372,496 (41.20 %) 15,730 (41.22 %) 11.5 0.90 (0.89–0.92) d 1,447 (38.94 %) 9.2 % 0.91 (0.85–0.98) c
Unknown 155,973 (4.68 %) 1,617 (4.24 %) 10.4 0.83 (0.79–0.88) d 180 (4.84 %) 11.1 % 1.12 (0.96–1.31)
Country of birth
Australia and New Zealand 2,411,315 (72.38 %) 26,794 (70.21 %) 11.1 1.00 2,575 (69.29 %) 9.6 % 1.00
UK, US & Canada 223,710 (6.71 %) 2,873 (7.53 %) 12.8 1.01 (0.97–1.05) 271 (7.29 %) 9.4 % 0.90 (0.79–1.02)
Non-English Europe 317,973 (9.54 %) 4,546 (11.91 %) 14.3 0.98 (0.95–1.02) 493 (13.27 %) 10.8 % 0.98 (0.88–1.08)
North Africa 61,595 (1.85 %) 487 (1.28 %) 7.9 0.67 (0.61–0.73) d 47 (1.26 %) 9.7 % 1.09 (0.82–1.46)
Asia 101,485 (3.05 %) 996 (2.61 %) 9.8 0.76 (0.71–0.81) d 98 (2.64 %) 9.8 % 1.11 (0.90–1.36)
Others 215,599 (6.47 %) 2,465 (6.46 %) 11.4 0.94 (0.90–0.98) d 232 (6.24 %) 9.4 % 1.01 (0.88–1.16)
Quartiles of SEIFA
1st quartile (most disadvantaged) 913,712 (27.42 %) 9,482 (24.85 %) 10.4 1.00 939 (25.27 %) 9.9 % 1.00
2nd quartile (disadvantaged) 862,580 (25.89 %) 8,843 (23.17 %) 10.3 1.00 (0.97–1.03) 900 (24.22 %) 10.2 % 1.05 (0.95–1.16)
3rd quartile (advantaged) 827,343 (24.83 %) 9,701 (25.42 %) 11.7 0.98 (0.95–1.01) 1,011 (27.21 %) 10.4 % 1.12 (1.01–1.23) c
4th quartile (most advantaged) 728,042 (21.85 %) 10,135 (26.56 %) 13.9 0.99 (0.95–1.03) 866 (23.30 %) 8.5 % 1.13 (1–1.27) c
Length of stay
2–4 days 1,495,477 (44.89 %) 4,803 (12.59 %) 3.2 1.00 567 (15.26 %) 11.8 % 1.00
4–9 days 1,056,167 (31.70 %) 10,724 (28.10 %) 10.2 2.78 (2.69–2.88) d 816 (21.96 %) 7.6 % 0.69 (0.62–0.76) d
Over 10 days 780,033 (23.41 %) 22,634 (59.31 %) 29.0 7.91 (7.65–8.17) d 2,333 (62.78 %) 10.3 % 0.82 (0.74–0.90) d
Major principal diagnostic diseasesb
Cardiac arrhythmias 74,686 (2.24 %) 657 (1.72 %) 8.8 - 22 (0.59 %) 3.3 % -
Chronic pulmonary disease 129,030 (3.87 %) 853 (2.24 %) 6.6 - 92 (2.48 %) 10.8 % -
Coagulopathy 5,455 (0.16 %) 211 (0.55 %) 38.7 - 15 (0.40 %) 7.1 % -
Congestive heart failure 71,705 (2.15 %) 971 (2.54 %) 13.5 - 130 (3.50 %) 13.4 % -
Diabetes with chronic complication 41,956 (1.26 %) 464 (1.22 %) 11.1 - 58 (1.56 %) 12.5 % -
Malignancies 206,407 (6.20 %) 3,796 (9.95 %) 18.4 - 860 (23.14 %) 22.7 % -
Metastatic solid tumour 49,332 (1.48 %) 1,427 (3.74 %) 28.9 - 368 (9.90 %) 25.8 % -
Peripheral vascular disease 26,225 (0.79 %) 425 (1.11 %) 16.2 - 61 (1.64 %) 14.4 % -
Pulmonary circulation disorders 1,520 (0.05 %) 73 (0.19 %) 48.0 - 10 (0.27 %) 13.7 % -
Renal disease 8,736 (0.26 %) 103 (0.27 %) 11.8 - 14 (0.38 %) 13.6 % -
Rheumatic disease 9,811 (0.29 %) 176 (0.46 %) 17.9 - 9 (0.24 %) 5.1 % -
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medical patients in all hospitals (Fig. 2). However, in private
hospitals, the incidence rate of HA-VTE peaked later, with
greater increments of 44 and 40 % in 2006 and 2007 for sur-
gical and medical patients, respectively (Fig. 2 and Add-
itional file 4). Higher variations were observed in stratified
trends - by public versus private, types of patients, hospital
peer groups and surgical types (see Additional file 5).
The adjusted HA-VTE case fatality rate significantly de-
clined by 22 % from 11.7 to 9.1 % over the study period
(Fig. 1). Stratified analysis illustrated in Fig. 3 showed
similar declines between public (2009 vs 2002: IRR =
0.74) and private hospitals (2009 vs 2002: IRR = 0.88),
surgical (IRR = 0.80) and medical patients (IRR = 0.59).
Large principal referral and metropolitan hospitals
Table 1 Study population, incidence rates and adjusted rate ratios of patients who developed HA-VTE and associated case fatality
(Continued)
Hospital type
Public 2,704,301 (81.17 %) 31,160 (81.65 %) 11.5 1.00 3,362 (90.47 %) 10.8 % 1.00
Private 627,376 (18.83 %) 7,001 (18.35 %) 11.2 1.03 (0.85–1.25) 354 (9.53 %) 5.1 % 0.55 (0.43–0.71) d
Peer hospital groups-Public
Principal referral (A1) 1,315,038 (48.63 %) 19,134 (61.41 %) 14.6 1.00 2,069 (61.54 %) 10.8 % 1.00
Ungrouped acute (A3) 73,569 (2.72 %) 765 (2.46 %) 10.4 0.67 (0.46–0.95) c 132 (3.93 %) 17.3 % 2.71 (1.48–4.97) d
Major metro- & non-metropolitan (B) 839,827 (31.06 %) 7,958 (25.54 %) 9.5 0.73 (0.60–0.89) d 817 (24.30 %) 10.3 % 1.22 (0.91–1.64)
District group 1 (C1) 245,005 (9.06 %) 1,933 (6.20 %) 7.9 0.64 (0.51–0.81) d 198 (5.89 %) 10.2 % 1.75 (1.22–2.50) d
District group 2 (C2) 230,862 (8.54 %) 1,370 (4.40 %) 5.9 0.48 (0.39–0.60) d 146 (4.34 %) 10.7 % 2.06 (1.44–2.95) d
Peer hospital groups-Private
Major m 409,555 (65.28 %) 4,961 (70.86 %) 12.1 1.00 213 (60.17 %) 4.3 % 1.00
District (22) 217,821 (34.72 %) 2,040 (29.14 %) 9.4 1.03 (0.64–1.64) 141 (39.83 %) 6.9 % 1.36 (0.79–2.34)
Local health district
Metropolitan 2,300,073 (69.04 %) 29,779 (78.04 %) 12.9 1.00 2,814 (75.73 %) 9.4 % 1.00
Rural & Regional NSW 1,031,604 (30.96 %) 8,382 (21.96 %) 8.1 0.69 (0.59–0.81) d 902 (24.27 %) 10.8 % 1.18 (0.95–1.45)
Total 3,331,677 38,161 11.4 3,716 9.7 %
111,493 (3.2 %) cases were excluded due to missing items
Incidence rates (IR) are crude and reported per 1000 patients
Incidence rate ratios (IRR) and related confident intervals (CI) were obtained using a Poisson mixed model and adjusted for patient and hospital characteristics
aIRRs were not adjusted for length of stay due to highly unbalanced distributions for medical versus surgical admissions
bNo RR is reported since this characteristic has not been included in the Poisson mixed model
cSignificant at 5 %; dsignificant at 1 %
Fig. 1 Adjusted trends of HA-VTE (per 1000 patients) and case fatality
(%) over the study period
Fig. 2 Adjusted trend of HA-VTE stratified by admission and hospital
type over the study period
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(coded as A1 and B) exhibited a significant decrease in
the HA-VTE associated fatality rate over the study
period (see Additional file 5).
The variation of outcomes between and with
hospital peer groups stratified by patients types
(medical versus surgical)
Table 2 shows that private hospitals exhibited a larger
variation between those hospitals with the lowest, and
those with the highest HA-VTE rate, and associated fatality
rates within each peer groups compared to public hospitals
peer groups. The major private hospital peer group showed
the highest variability of HA-VTA between the top and
bottom 20 % percentile performers (IRR = 5.33), followed
by district group 2 public hospitals (IRR = 2.94) and district
private hospital groups (IRR = 2.44). For HA-VTE case
fatality, the major private hospital group had the largest
variability (IRR = 6.23), followed by the district private hos-
pital group (IRR = 5.72) and then the district group 1
public hospitals (IRR = 3.77). These within group varia-
tions were almost replicated for surgical patients, whereas
for medical patients, the district group 1 public hos-
pital showed the highest variability for HA-VTE rates
(IRR = 4.32) and principal referral public hospital group
had the highest variability for HA-VTE case fatality
(IRR = 15.65). The significant negative correlations be-
tween individual hospital HA-VTE rates and HA-VTEs
case fatality rates for private hospital peer groups im-
plied that hospitals with the highest HA-VTE rate
tended to have a lower rate of subsequent death. There
were no such associations within other public hospitals
peer groups.
Discussion
In this large cohort study of all NSW acute hospitals
during 2002–2009, we found that over 1 in 100 patients
developed HA-VTE. Of these, one in ten subsequently
died during hospitalisation. The adjusted HA-VTE inci-
dence peaked in 2004 and then declined afterwards,
while the HA-VTE case fatality decreased by 22 % over
the study period. Risk of HA-VTE for surgical patients
was double the risk for medical patients, but fatality rate
was similar. Medical patients admitted at private hospi-
tals experienced higher risks of HA-VTE; whereas surgi-
cal patients were at higher risk of subsequent death in
public hospitals. There were significant variations in
HA-VTE incidence and case fatality between, and
within, hospital peer groups. Among public hospitals,
principal referral hospitals had a higher HA-VTE inci-
dence but lower associated deaths compared to the
smaller hospitals. Whereas there was no difference be-
tween major and smaller private hospitals. Overall,
between-hospital variation tended to be higher among
private hospitals, particularly for major facilities. Smaller
public hospitals often exhibited a larger variation in both
rates.
The incidence of HA-VTE in NSW hospitals was
almost five fold the rate (11.4 vs 2.4 per 1000 patients
with VTE as secondary diagnoses) previously reported in
Australia (Australian Institute of Health and Welfare
(AIHW) 2010). Our rate among surgical patients was
higher than those reported for patients who underwent
elective surgery in NSW or U.S. hospitals (13 vs 2–4.5
per 1000 patients) [12, 14, 21]. In contrast, our observed
rate for medical patients was broadly consistent with
those reported for U.S. hospitals (4.5 vs 2.5 to 5.1 per
1000 patients) [42, 43]. No comparable measures are
available for overall HA-VTE case fatality in an Australian
setting. For surgical patients, case fatality rate was similar
to the previous report in NSW (9.8 % vs. 7.9 and 8.3 %)
[14, 21]; for medical patients, it was lower than the U.S
hospitals’ rate (9.6 % vs 15 to 16.5 %) [42, 44]. Differences
in case identification introduced by varying ICD codes
and systems, and inclusion of VTE incidents for all surgi-
cal patients in this study, compared to patients who just
underwent elective surgery in other reports may have con-
tributed to the discrepancies.
Patients with cancer, vascular and clotting disorders
are at high risk of developing VTE [5, 44]. The high fa-
tality rate found among cancer patients is consistent
with previous studies reporting cancer as a major risk
factor of developing PE and a high fatality rate [45].
Our finding that medical patients were less likely to de-
velop VTE compared to surgical patients echoes the
fact that surgery and in particular major procedures
such as orthopaedic or AAA repair are known risk
factors [1, 21, 46].
Fig. 3 Adjusted trend of post HA-VTE case fatality stratified by admission
and hospital type over the study period
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The recording and reporting of post-operative VTE
as a patient safety outcome may have contributed to
halving of the HA-VTE rates amongst surgical patients
in the U.S. [12, 15]. No such a drop in Australia was
evident [21, 23]. However, the decreasing trajectory in
HA-VTE incidents and in particular in associated mor-
tality after adjusting for varied length of stay over time,
coincided with the release and adherence with VTE
prevention guidelines in Australia [2, 47].
Compliance with VTE prevention guidelines was re-
portedly suboptimal for hospitalised patients and medical
patients were up to 50 % less likely than surgical patients
to receive adequate VTE prophylaxis [48–50]. Other
studies have shown a smaller improvement in post VTE
survival for medical patients [51, 52] which was not evi-
dent in our study. Extension of the VTE prevention efforts
to medical patients as recently targeted in Australia [11]
and elsewhere [53] and routine measurement of associated
indictors could reduce incidences and adverse outcome.
We found that the incidence of HA-VTE was lower
for medical patients at public versus private hospitals; but
public hospitals had higher subsequent case fatalities, in
particular for surgical patients. Differences in compliance
with VTE prevention guidelines can result in varying VTE
measures across hospitals. Altered length of stay have
been contributed to the differences in HA-VTE outcomes
Table 2 Rates, adjusted rate ratios and association of outcomes between the best and worst performers within hospital peer groups
Hospital peer group Hospital HA-VTE HA-VTE case fatality Correlation coefficient
n Lowest (IR) Highest (IR) IRR (95 % CI) Lowest (%) Highest (%) IRR (95 % CI) (95 % CI)
All admissions
Public hospitals
Principal referral (A1) 17 11.0 22.9 2.09 (2–2.19) b 7.7 % 13.8 % 1.93 (1.64–2.27) b −0.38 (-0.76–0.19)
Major metro- &
non-metropolitan (B)
22 6.8 12.6 1.70 (1.58–1.84) b 6.9 % 15.0 % 2.13 (1.73–2.63) b −0.22 (-0.59–0.22)
District group 1 (C1) 13 5.8 11.7 2.02 (1.77–2.31) b 5.9 % 20.5 % 3.77 (2.41–5.91) b −0.35 (-0.76–0.25)
District group 2 (C2) 30 2.8 10.4 2.94 (2.39–3.62) b 4.7 % 14.7 % 3.47 (1.94–6.19) b 0.04 (-0.33–0.39)
Private hospitals
Major (21) 10 4.0 24.7 5.33 (4.62–6.16) b 1.4 % 10.5 % 6.23 (4.25–9.13) b −0.63 (-0.9–0.01) a
District (22) 12 6.0 14.3 2.44 (2.05–2.9) b 2.8 % 12.3 % 5.72 (3.1–10.58) b −0.82 (-0.95–0.46) b
Medical admissions
Public hospitals
Principal referral (A1) 17 3.3 7.6 2.24 (1.75–2.87) b 1.3 % 18.3 % 15.65 (3.73–65.58) b −0.08 (-0.61–0.49)
Major metro- &
non-metropolitan (B)
22 2.3 4.5 2.03 (1.59–2.58) b 0.0 % 20.1 % 0.29 (-0.15–0.63)
District group 1 (C1) 13 1.5 5.5 4.32 (2.72–6.86) b 4.0 % 20.0 % 5.81 (1.58–21.41) b −0.36 (-0.76–0.23)
District group 2 (C2) 30 2.3 7.0 3.65 (2.64–5.06) b 0.0 % 27.8 % −0.13 (-0.47–0.24)
Private hospitals
Major (21) 10 5.1 13.6 2.52 (1.48–4.29) b 1.1 % 20.0 % 0.32 (-0.39–0.79)
District (22) 12 3.6 12.9 3.88 (2.55–5.92) b 4.6 % 16.7 % 2.57 (0.66–9.97) −0.67 (-0.9–0.16) a
Surgical admissions
Public hospitals
Principal referral (A1) 17 11.8 25.0 2.12 (2.02–2.22) b 8.9 % 14.0 % 1.74 (1.52–1.99) b −0.38 (-0.76–0.19)
Major metro- &
non-metropolitan (B)
22 7.9 14.3 1.74 (1.61–1.88) b 7.2 % 14.7 % 2.01 (1.62–2.49) b −0.21 (-0.58–0.23)
District group 1 (C1) 13 7.2 13.7 1.88 (1.63–2.16) b 5.8 % 20.8 % 4.11 (2.5–6.75) b −0.30 (-0.73–0.3)
District group 2 (C2) 30 2.9 14.7 3.75 (2.83–4.98) b 3.8 % 14.9 % 4.37 (2.06–9.26) b 0.05 (-0.32–0.4)
Private hospitals
Major (21) 10 3.6 25.0 6.07 (5.2–7.09) b 1.7 % 11.2 % 5.88 (3.77–9.18) b −0.36 (-0.81–0.35)
District (22) 12 5.9 11.8 2.37 (1.99–2.81) b 2.2 % 11.3 % 6.88 (3.24–14.62) b −0.72 (-0.92–0.25) b
Incidence rates (IR) are crude and reported per 1000 patients
Incidence rate ratios (IRR) and related confident intervals (CI) were obtained using Poisson mixed models and adjusted for patient characteristics. Those hospitals
with the lowest rate were set as the reference level
Ungrouped acute peer group within public hospitals was removed from analysis due to small number of hospitals within this group
aSignificant at 5 %; bsignificant at 1 %
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between two sectors [44, 54], however we here adjusted
for length of stay across hospitals, offsetting the influence
of shorter stay in private hospitals [30]. A difference in
case mix may have contributed to discrepancies between
the two sectors.
Our finding that NSW larger hospitals had excess
HA-VTE incidents but lower fatalities is consistent with
hospital-volume effect reported for HA-VTE [21] and
mortality [55–57]. Undertaking patients with higher
surgical complexity and multiple comorbidities as well
as better diagnosis of high-risk but asymptomatic VTE
in larger hospitals [58] may have contributed to ele-
vated HA-VTE rates in major hospitals. On the other
hand, underreporting, failure to diagnose or a mis-coding
of HA-VTE may be more common amongst smaller hos-
pitals [22, 37, 59]. Subsequently, majority of the identified
VTE cases in smaller hospitals are those who developed
PE and were more likely to die. A higher rate of diagnosis,
and lower case fatality, may reflect a greater adherence to
evidence-based treatment guidelines and less failure-to-
rescue. Therefore, study of HA-VTE incidents alone may
be misleading and more research is required to identify
contributing factors to both the incidence rate and case
fatality.
Our study has several implications. Expansion of VTE
prevention programs to private hospitals and medical
patients are required. The large variation of HA-VTE
rates between and within different sectors and hospital
peer groups suggests that there is room for improvement
in the diagnosis, prevention and treatment of HA-VTE.
Development of measures for hospital acquired VTE, and
the continual monitoring and public reporting of the VTE
incidence and mortality for benchmarking and quality im-
provement purposes at local, regional and national level
should be considered [2, 60].
This study benefited from a large population-based co-
hort across all acute hospitals within the most populated
region in Australia. We utilised two measures that were
comparable to well-established VTE and case fatality indi-
cators within the patient safety literature, which allowed
us to differentiate prevention versus treatment of VTE as
well as benchmarking internally and externally. However
our study has multiple limitations. The rates of HA-VTE
may be prone to two biases: a) overestimation due to pos-
sible inclusion of community base VTE cases that were re-
corded as secondary diagnoses; and b) underestimation
due to neglecting VTE cases developed during hospitalisa-
tion but not diagnosed prior to discharge [44]. This sug-
gests that bias may be reduced by the utilisation of newly
adopted condition onset variables (whether or not mor-
bidity was present on admission) in hospital adminis-
trative datasets [61] and data linkage in the follow-up
period [62]. The accuracy of our results were limited to the
quality of documentation and clinical coding practices [37],
and thus can be improved via clinical chart review. Further-
more inclusion of broader confounding factors such as
severity of patients such as Charlson and Elixhauser scores
based on accurate morbidity data, body mass index and
smoking can provide additional insight on the observed
trends [63, 64].
Conclusion
There incidence and case fatality rate of HA-VTE in
NSW hospital in-patients is decreasing. The significant
variability for HA-VTE incidents and case fatality between
medical and surgical patients within public and private
sectors and between hospital peer groups suggests poten-
tial for further improvement in both prevention and treat-
ment of HA-VTE. Routine measurement and reporting of
both HA-VTE incidence and associated mortality can pro-
vide policy-makers, clinicians and researchers with oppor-
tunities to monitor and improve performance.
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